Bio-Rad Laboratories stock has rebounded in the short term, yet the current price around US$352 still screens as expensive relative to its intrinsic value estimate and market multiples. After a 5 year period where the share price fell 54.7%, the recent strength sits against valuation checks that point to a premium rather than a clear bargain.

• Over the last 5 years, Bio-Rad Laboratories is down 54.7%, which suggests long term holders have taken a significant hit even though the recent share price has improved.
• The investment case can be influenced by how steadily Bio-Rad Laboratories converts its revenue into cash flow on one side, and by any pressure on profitability or capital needs that could weigh on those future cash flows on the other.
• Bio-Rad Laboratories passes only 1 out of 6 valuation checks, which indicates the stock currently leans expensive on the broader measures rather than standing out as cheap.

The issue now is whether the recent rally in Bio-Rad Laboratories leaves enough upside compared with what the intrinsic value estimate and valuation multiples suggest.

Does Bio-Rad Laboratories Look Pricey on Cash Flow?

The Discounted Cash Flow (DCF) model here uses projected free cash flows to estimate what Bio-Rad Laboratories might be worth today. On the latest figures, the company generated about $325.8m of free cash flow over the last twelve months, and the model assumes these cash flows continue to grow rather than shrink over the coming years.

When those cash flows are discounted back, the DCF model points to an intrinsic value of about $304 per share for Bio-Rad Laboratories. That is below the recent share price around $352, which implies the stock trades at roughly a 16.1% premium to this intrinsic value estimate.

On this DCF view, Bio-Rad Laboratories stock currently screens as overvalued relative to its projected cash flows.

Our Discounted Cash Flow (DCF) analysis suggests Bio-Rad Laboratories may be overvalued by 16.1%. Discover 51 high quality undervalued stocks or create your own screener to find better value opportunities.

Is Bio-Rad Laboratories Getting Expensive on Earnings?

The P/E ratio is a useful way to look at Bio-Rad Laboratories because earnings are a key focus for many Life Sciences investors. On this measure, Bio-Rad trades on a P/E of about 42.4x, which sits above the Life Sciences industry average of roughly 37.0x and also above the peer average of about 100.2x.

A tailored fair P/E ratio for Bio-Rad Laboratories is estimated at around 16.2x, based on factors such as its sector, size and risk profile. Compared with the current 42.4x, the stock trades at a substantial premium to this fair multiple, so the market is pricing Bio-Rad at a higher earnings valuation than this framework would suggest.

On the P/E lens, Bio-Rad Laboratories stock currently appears overvalued relative to the earnings multiple that would typically be expected.

The Bio-Rad Laboratories Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Bio-Rad Laboratories pick up where this valuation puzzle leaves off. They translate Bio-Rad Laboratories' current share price into clear assumptions about future growth, margins and earnings that would need to hold for the stock to be worth materially more or less than today. Rather than relying on a single multiple or model, each narrative sets out the assumptions behind its fair value so you can compare them with actual results over time. These Narratives sit on Simply Wall St's Community page.

Bullish and bearish narratives on Bio-Rad Laboratories sit far apart, even though both lean on the same set of products and end markets.

Bull case: roughly fairly valued

"Automation, advanced data analytics, and digital transformation initiatives are set to yield stepwise improvements in operational efficiency and scale. This is expected to enable Bio-Rad to reduce SG&A expenses as a percentage of sales and directly boost operating and net margins..."

Bear case: 28% overvalued

"Persistent global healthcare cost containment and increasing governmental price controls are expected to constrain reimbursement growth for diagnostics and laboratory products. This may place a structural cap on Bio-Rad's long-term revenue expansion and challenge its ability to drive top-line growth as pricing pressure intensifies worldwide..."

Do you think there's more to the story for Bio-Rad Laboratories? Head over to our Community to see what others are saying!

The Bottom Line

Bio-Rad Laboratories currently screens as overvalued, with the Discounted Cash Flow (DCF) intrinsic value estimate sitting below the recent share price and the main earnings multiple also pointing to a premium. Both approaches line up with the broader valuation checks, which are weak and do not flag clear value on today’s numbers. For investors, the key question is whether Bio-Rad can deliver the margin and earnings progress that bullish narratives assume. The answer to that, rather than the recent share price recovery, is likely to decide whether the current valuation holds or proves too rich over time.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.